세계의 상처 괴사조직제거 기기 시장 : 시장 인사이트, 경쟁 구도, 시장 예측(2032년)

Wound Debridement Devices Market by Product Type (Gels, Ointments, Surgical Devices, Medical Gauzes, Ultrasonic Devices, Debridement Pads, and Others), Method (Autolytic, Enzymatic, Surgical, Mechanical, Ultrasonic, and Others), Wound Type (Pressure Ulcers, Diabetic Foot Ulcers, Venous Leg Ulcers, Burn Wound, and Others), End-User (Hospitals, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2032 owing to the growing prevalence of chronic and non-healing wounds, increase in traumatic injuries, and increase in product development activities among the key market players globally.

The wound debridement devices market was valued at USD 4,993.72 million in 2024, growing at a CAGR of 5.53% during the forecast period from 2025 to 2032 to reach USD 7,660.46 million by 2032. The growing prevalence of chronic and non-healing wounds, such as diabetic foot ulcers, pressure sores, and venous leg ulcers, is significantly boosting the demand for wound debridement devices. These conditions require regular and effective wound management to prevent infections and promote healing. Additionally, the rising number of traumatic injuries from accidents and surgeries has led to an increased need for timely wound cleaning and tissue removal. Additionally, increasing R&D activities and product launches by key players are factors that are expected to drive the wound debridement devices market significantly during the forecast period from 2025 to 2032.

Wound Debridement Devices Market Dynamics:

According to Diabetes Feet Australia (DFA) (2022), in Australia, approximately 300,000 individuals per 100,000 population are at risk of developing diabetic foot disease (DFD), with 50,000 people already living with the condition. Alarmingly, 12,500 individuals have undergone diabetes-related amputations, and 1,000 are hospitalized due to DFD.

In African countries, the burden is similarly significant. For instance, the International Diabetes Federation (IDF) Atlas Report (2022), highlights that the prevalence of diabetic foot ulcers (DFUs) ranges between 10% and 30%, while the incidence of lower limb amputations (LLAs) varies from 3% to 35%, reflecting disparities in diabetes care and wound management across the region. These ulcers often become chronic and prone to infection due to poor circulation and impaired healing, necessitating frequent and effective wound debridement to remove necrotic tissue and promote recovery. Without proper debridement, these wounds can worsen, leading to severe infections and even amputation, thereby boosting the overall market of wound debridement devices.

Additionally, according to the World Health Organization (2023), approximately 20 and 50 million more people suffered non-fatal injuries, with many incurring a disability. These injuries often lead to tissue damage, contamination, or necrosis, which require regular debridement to prevent infection and support optimal healing. Especially in cases of deep lacerations, abrasions, or burns, removing dead tissue is critical to avoid complications such as sepsis or delayed healing.

Moreover, the increase in product approvals and launches further boosts the market for wound debridement devices. For instance, in March 2023, Vaporox, a Denver-based medical device company, received clearance from the U.S. Food and Drug Administration for its next-generation VHT-200 medical device system for healing chronic wounds. These wounds, which typically do not respond to conventional treatment, represented a significant unmet medical need for millions of individuals suffering from diabetic foot ulcers.

Considering above mentioned factors, the global wound debridement devices market is poised for substantial growth during the forecast period of 2025 to 2032.

However, market growth may be constrained by the risk of infections and other complications associated with the procedure. Additionally, competition from alternative treatment options presents a significant challenge to widespread adoption.

Wound Debridement Devices Market Segment Analysis:

Wound Debridement Devices Market by Product Type (Gels, Ointments, Surgical Devices, Medical Gauzes, Ultrasonic Devices, Debridement Pads, and Others), Method (Autolytic, Enzymatic, Surgical, Mechanical, Ultrasonic, and Others), Wound Type (Pressure Ulcers, Diabetic Foot Ulcers, Venous Leg Ulcers, Burn Wound, and Others), End-User (Hospitals, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the wound debridement devices market, the gels category is projected to hold the largest revenue share in 2024. This dominance is primarily due to its effective, non-invasive, and patient-friendly properties. Debridement gels are formulated to facilitate the natural removal of necrotic tissue through autolytic debridement, a process that harnesses the body's enzymes to break down dead tissue while preserving healthy tissue. This gentle mechanism makes gels particularly suitable for patients with sensitive or chronic wounds.

A key advantage of debridement gels lies in their moisture-retentive nature, which helps maintain an optimal wound environment essential for accelerating healing and reducing infection risks. Their ease of application and minimal intervention requirements further enhance patient compliance, making them ideal for managing chronic wounds such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers. The growing demand for minimally invasive wound care solutions, alongside the rising global prevalence of chronic wounds, particularly those associated with diabetes, obesity, and an aging population, has been a significant catalyst for the increased adoption of debridement gels.

Innovations in hydrogel-based formulations now incorporate antimicrobial agents, enhancing their ability to combat infections while promoting faster wound closure. These next-generation gels offer dual benefits, effective debridement and infection prevention, making them increasingly preferred by healthcare professionals. For example, in May 2023, Kane Biotech Inc. announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its coactiv+(TM) Antimicrobial Wound Gel. The product was approved for use in managing various types of wounds, including diabetic foot and leg ulcers, pressure ulcers, first- and second-degree burns, partial- and full-thickness wounds, large surface area wounds, and surgical incisions in adult patients.

Considering these multifaceted advantages, the gel category is projected to experience substantial growth during the forecast period of 2025 to 2032, playing a pivotal role in propelling the overall wound debridement devices market forward.

North America is expected to dominate the overall wound debridement devices market:

North America is anticipated to dominate the wound debridement devices market in 2024. This regional domination is attributed to several factors, including the increasing patient population affected by lifestyle disorder such as diabetes, increase in traumatic injuries such as burns, road accident injuries along with strong presence of key market players with robust distribution networks are the factors that are driving the expansion of the market in the North America.

Complications of diabetes, such as diabetic foot ulcers (DFUs) and lower-limb amputations (LLAs), remains a major public health concern in the U.S. According to the Centers for Disease Control and Prevention (CDC) (2024), approximately 38.4 million Americans accounting for 11.6% of the U.S. population were living with diabetes. Notably, 80% of LLAs are attributed to diabetes-related complications, underscoring the critical role of wound debridement devices in preventing amputations and managing chronic wounds.

The increasing prevalence of traumatic injuries, including those from burns and road accidents, also fuels market demand. According to the American Burn Association (ABA), over 486,000 burn injuries require medical treatment in the U.S. annually, many of which necessitate debridement to prevent infection and promote healing. As healthcare systems focus more on reducing the burden of injury-related complications and improving patient recovery times, hospitals, trauma centers, and outpatient clinics are increasingly adopting advanced wound debridement devices. Furthermore, the rise in emergency room visits and surgeries following such injuries is creating a sustained demand for efficient, easy-to-use, and safe debridement tools, thereby fueling growth in the wound debridement devices market.

Additionally, the presence of leading market players is another key growth driver. Companies such as Zimmer Biomet, Medline Industries, LP, DeRoyal Industries, Inc., and others have established extensive distribution networks, ensuring the availability of advanced debridement solutions across hospitals, outpatient settings, and home care environments. These players are continuously investing in research and development to introduce innovative products with enhanced efficacy, patient comfort, and antimicrobial properties, further boosting market growth. For instance, in December 2022, MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the U.S. Food and Drug Administration (FDA) approved NexoBrid(R) (anacaulase-bcdb) for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.

Collectively, these factors are expected to propel the wound debridement devices market in the region, solidifying its dominant position in the global landscape throughout the forecast period from 2025 to 2032.

Wound Debridement Devices Market key players:

Some of the key market players operating in the wound debridement devices market include B. Braun Melsungen AG, Essity Aktiebolag, PAUL HARTMANN Limited, Coloplast Group, Zimmer Biomet, Medline Industries, LP, DeRoyal Industries, Inc., Solascure Limited, Smith+Nephew, L&R Group, Medaxis AG, Bioventus, Arobella Medical, Convatec Inc., BioMonde, Soring GmbH, Welcare Industries S.p.A., Sanara MedTech Inc., Molnlycke AB, Hollister Incorporated, and others.

Recent Developmental Activities in the Wound Debridement Devices Market:

• In February 2025, Biomiq Inc., a Canadian leader in advanced wound care solutions, introduced PureGel(TM), a super-oxidizing nano-hydrogel designed for the extended delivery of pure and stable hypochlorous acid (HOCl) onto skin, wounds, and burns.
• In February 2021, Axio Biosolutions announced that it secured CE Certification in Europe for its next-generation advanced wound care product line, MaxioCel. This innovative product range is designed to enhance patient comfort and has demonstrated accelerated healing for various chronic wounds, including pressure ulcers, diabetic foot ulcers, venous leg ulcers, and cavity wounds in clinical studies.

Key takeaways from the wound debridement devices market report study

• Market size analysis for the current wound debridement devices market size (2024), and market forecast over 8 years (2025 to 2032)
• The top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the wound debridement devices market
• Various opportunities are available for the other competitors in the wound debridement devices market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current wound debridement devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the wound debridement devices market growth in the future?

Target audience who can benefit from this wound debridement devices market report study

• Wound debridement device providers
• Research organizations and consulting companies
• Wound debridement devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in wound debridement devices
• Various end-users who want to know more about the wound debridement devices market and the latest developments in the wound debridement devices market

Frequently Asked Questions for the Wound Debridement Devices Market:

1. What are wound debridement devices?

• Wound debridement is the medical process of removing non-viable, dead, damaged, or infected tissue and debris from a wound to promote optimal healing. Debridement can be performed using various methods, including surgical, mechanical, enzymatic, autolytic, and biological techniques, depending on the nature and severity of the wound.

2. What is the market for wound debridement devices?

• The wound debridement devices market was valued at USD 4,993.72 million in 2024, growing at a CAGR of 5.53% during the forecast period from 2025 to 2032 to reach USD 7,660.46 million by 2032.

3. What are the drivers for the wound debridement devices market?

• The growing prevalence of chronic and non-healing wounds, such as diabetic foot ulcers, pressure sores, and venous leg ulcers, is significantly boosting the demand for wound debridement devices. These conditions require regular and effective wound management to prevent infections and promote healing. Additionally, the rising number of traumatic injuries from accidents and surgeries has led to an increased need for timely wound cleaning and tissue removal. Additionally, increasing R&D activities and product launches by key players are factors that are expected to drive the wound debridement devices market significantly during the forecast period from 2025 to 2032.

4. Who are the key players operating in the wound debridement devices market?

• Some of the key market players operating in the wound debridement devices market include B. Braun Melsungen AG, Essity Aktiebolag, PAUL HARTMANN Limited, Coloplast Group, Zimmer Biomet, Medline Industries, LP, DeRoyal Industries, Inc., Solascure Limited, Smith+Nephew, L&R Group, Medaxis AG, Bioventus, Arobella Medical, Convatec Inc., BioMonde, Soring GmbH, Welcare Industries S.p.A., Sanara MedTech Inc., Molnlycke AB, Hollister Incorporated, and others.

5. Which region has the highest share in the wound debridement devices market?

• Among all the regions, North America is anticipated to dominate the wound debridement devices market in 2024. This regional leadership is attributed to several factors, including the increasing patient population affected by lifestyle disorder such as diabetes, increase in traumatic injuries such as burns, road accident injuries along with strong presence of key market players with robust distribution networks are the factors that are driving the expansion of the market in the North America.

Table of Contents

1. Wound Debridement Devices Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Wound Debridement Devices Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Wound Debridement Devices Market Key Factors Analysis

• 5.1. Wound Debridement Devices Market Drivers
  • 5.1.1. The growing prevalence of chronic and non-healing wounds
  • 5.1.2. Increase in traumatic injuries such as burns, road accident injuries
  • 5.1.3. Increasing product development activities among the key players
• 5.2. Wound Debridement Devices Market Restraints and Challenges
  • 5.2.1. Risk of infection & complications
  • 5.2.2. Competition from alternative therapies
• 5.3. Wound Debridement Devices Market Opportunities
  • 5.3.1. Integration of artificial intelligence (AI) with wound debridement devices
  • 5.3.2. Advancements and innovations in wound care technology, such as low-frequency ultrasound devices and hydrosurgical debridement tools

6. Wound Debridement Devices Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Wound Debridement Devices Market Assessment

• 7.1. By Product Type
  • 7.1.1. Gels
  • 7.1.2. Ointments
  • 7.1.3. Surgical Devices
  • 7.1.4. Medical Gauzes
  • 7.1.5. Ultrasonic Devices
  • 7.1.6. Debridement Pads
  • 7.1.7. Others
• 7.2. By Method
  • 7.2.1. Autolytic
  • 7.2.2. Enzymatic
  • 7.2.3. Surgical
  • 7.2.4. Mechanical
  • 7.2.5. Ultrasonic
  • 7.2.6. Others
• 7.3. By Wound Type
  • 7.3.1. Pressure Ulcers
  • 7.3.2. Diabetic Foot Ulcers
  • 7.3.3. Venous Leg Ulcers
  • 7.3.4. Burn Wound
  • 7.3.5. Others
• 7.4. By End-User
  • 7.4.1. Hospitals
  • 7.4.2. Clinics
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.1.2. Canada Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.1.3. Mexico Wound Debridement Devices Market Size in USD million (2022-2032)
  • 7.5.2. Europe
    • 7.5.2.1. France Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.2.2. Germany Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.2.3. United Kingdom Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.2.4. Italy Wound Debridement Devices market size in USD million (2022-2032)
    • 7.5.2.5. Spain Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.2.6. Rest of Europe Wound Debridement Devices Market Size in USD million (2022-2032)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.3.2. Japan Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.3.3. India Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.3.4. Australia Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.3.5. South Korea Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.3.6. Rest of Asia-Pacific Wound Debridement Devices Market Size in USD million (2022-2032)
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.4.2. Africa Wound Debridement Devices Market Size in USD million (2022-2032)
    • 7.5.4.3. South America Wound Debridement Devices Market Size in USD million (2022-2032)

8. Wound Debridement Devices Market Company and Product Profiles

• 8.1. B. Braun Melsungen AG
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Essity Aktiebolag
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. PAUL HARTMANN Limited
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Coloplast Group
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Zimmer Biomet
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Medline Industries, LP
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. DeRoyal Industries, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Solascure Limited
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Smith+Nephew
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. CL&R Group
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Medaxis AG
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Bioventus
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Arobella Medical
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Convatec Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. BioMonde
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Soring GmbH
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Welcare Industries S.p.A
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Sanara MedTech Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Molnlycke AB
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Hollister Incorporated
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us